Sbir phase I topic 396 evaluation of [18F]F-arag, a T cell-specific pet agent, as an imaging biomarker predictive of response to immunotherapies - moonshot
Ended Definitive Contract Awarded Last action
- Contract number
- 75N91019C00012
- Awardee
-
Cellsight Technologies, Inc. UEI E3UQXACGFR43
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $300,000
Award facts
- Opportunity
-
- PHS201901 Solicitation number
- Contract value 100% obligated
- $300,000.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 95 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- San Francisco, CA 94107, USA
- Research
- SBIR Program Phase I Action
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $300,000 |
About this award
This is a $300,000 Firm Fixed Price contract awarded by the National Institutes of Health (NIH) National Cancer Institute (NCI) to Cellsight Technologies, Inc., a woman-owned small business, under the Small Business Innovation Research (SBIR) program. The purpose of the contract is to evaluate [18F]F-ARAG, a T cell-specific Positron Emission Tomography (PET) imaging agent, as a biomarker to predict response to cancer immunotherapies. This Phase I SBIR contract builds on a previous $2 million Phase II SBIR contract awarded to Cellsight to develop [18F]F-ARAG for non-small cell lung cancer immunotherapy monitoring. Cellsight also supports related research through subawards on using [18F]F-ARAG to detect cardiotoxicity associated with cancer treatments.
Quick answers
Who was awarded contract 75N91019C00012?
75N91019C00012 was awarded to Cellsight Technologies, Inc. by National Cancer Institute (National Institutes of Health) on September 16, 2019.
How much is contract 75N91019C00012 worth?
The government has obligated $300,000 on 75N91019C00012.
Was contract 75N91019C00012 competed?
The extent of competition for 75N91019C00012 was full and open competition after exclusion of sources. The government received 95 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award